SCHEMBL3558254

SCHEMBL3558254

OC1(c2ccccc2Cl)CCCC[N]1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC4 P56524 2/20 0.45
GRIN1 Q05586 4/20 0.39
GRIN2A Q12879 4/20 0.39
SLC6A4 P31645 3/20 0.39
GRIN2D O15399 2/20 0.39
GRIN3B O60391 2/20 0.39
GRIN2B Q13224 2/20 0.39
GRIN2C Q14957 2/20 0.39
GRIN3A Q8TCU5 2/20 0.39
OPRK1 P41145 1/20 0.39
LMNA P02545 1/20 0.39
OPRM1 P35372 1/20 0.39
CACNA1C Q13936 1/20 0.39
HTT P42858 1/20 0.37
HDAC3 O15379 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC2 Q92769 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
ADORA3 P0DMS8 1/20 0.35
SLC6A2 P23975 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3167974 0.76 TAAR1 (0.46) HDAC4GRIN1GRIN2ASLC6A4GRIN2D
SCHEMBL3553606 0.74 AKR1C1 (0.42) HDAC4GRIN1GRIN2ASLC6A4GRIN2D
SCHEMBL2265295 0.72 GRIN1 (0.45) GRIN1GRIN2ASLC6A4GRIN2BOPRK1
SCHEMBL30089861 0.72 HDAC4 (0.51) HDAC4GRIN1GRIN2ASLC6A4GRIN2D
SCHEMBL8986019 0.72 HDAC4 (0.51) HDAC4GRIN1GRIN2ASLC6A4GRIN2D
SCHEMBL3173222 0.71 DRD2 (0.42) HDAC4SLC6A4SLC6A2MEN1KMT2A
SCHEMBL6072230 0.70 TAAR1 (0.47) HDAC4GRIN1GRIN2ASLC6A4GRIN2D
SCHEMBL27035066 0.70 HDAC4 (0.49) HDAC4GRIN1GRIN2ASLC6A4GRIN2D
SCHEMBL6833553 0.68 AKR1C1 (0.39) HDAC4OPRK1OPRM1
SCHEMBL23227575 0.68 HDAC4 (0.44) HDAC4GRIN1GRIN2ASLC6A4GRIN2D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7834015-B2 treatment of cancer, inflammatory diseases, reperfusion injuries, ischaemic conditions, stroke, renal failure, cardiovascular diseases, neurodegenerative diseases, retroviral infections, retinal damage, skin senescence and UV skin damage, and as chemosensitizers or radiosensitizers for cancer treatment INSTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) 2010-11-16 US disclosed
US-20090209523-A1 Pyrrolo[1,2-A] Pyrazin-1(2H)-One and Pyrrolo[1,2-D][1,2,4]Triazin-1(2H)-One Derivatives as Inhibitors of Poly(Adp-Ribose)Polymerase (Parp) ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) 2009-08-20 US disclosed
EP-2032140-A1 PYRROLO[1,2-A]PYRAZIN-1(2H)-ONE AND PYRROLO[1,2-D][1,2,4]TRIAZIN-1(2H)-ONE DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE(PARP) Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. (IT) 2009-03-11 EP disclosed
WO-2007138355-A1 PYRROLO[1,2-A]PYRAZIN-1(2H)-ONE AND PYRROLO[1,2-D][1,2,4]TRIAZIN-1(2H)-ONE DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE(PARP) ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) 2007-12-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090209523-A1 Pyrrolo[1,2-A] Pyrazin-1(2H)-One and Pyrrolo[1,2-D][1,2,4]Triazin-1(2H)-One Derivatives as Inhibitors of Poly(Adp-Ribose)Polymerase (Parp) PARP1, PARP2, PARP11 HDAC4 2590/4885GRIN1 2628/4885GRIN2A 3524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.